Endonovo Therapeutics, Inc. provided earnings guidance for the first quarter ended March 31, 2019. Revenue projections for the first quarter ended March 31, 2019 are expected to increase by roughly 80% over the same quarter last year. Revenue for the quarter will exceed $40,000, as compared to $22,173 during the same period in the prior year.